US FDA plans September meeting to discuss IOM proposal to scrap 510(k)
This article was originally published in Clinica
The US Food and Drug Administration is to hold a public meeting on 16 September to discuss the controversial Institute of Medicine report that calls for the agency to replace the pre-market notification process it uses to clear most medium- and low-risk medical devices with an entirely new framework.
You may also be interested in...
An independent audit of the new EU Clinical Trials Information System has finally commenced, indicating that plans are on track for the EU Clinical Trial Regulation to be implemented from December 2021.
EU regulators have agreed on supplementary pharmacovigilance requirements applicable to COVID-19 vaccines following approval.
The UK Medicines and Healthcare products Regulatory Agency wants clinical trial sponsors to integrate available regulatory flexibilities into normal practice so that their studies can withstand further potential disruptions from the COVID-19 pandemic.